Bristol-Myers Squibb (BMS) has entered a research partnership with the Harvard Stem Cell Institute’s Harvard Fibrosis Network for the development of fibrotic disease therapies.

The Harvard Fibrosis Network includes researchers from the schools and affiliated hospitals of Harvard University, and the alliance will involve investigators from these institutions.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Over a period of three years, researchers will work with BMS scientists on four projects.

The projects will focus on hepatic and cardiac fibrosis segments and aim to discover non-invasive biomarkers and identify new targets for potential anti-fibrotic drugs.

Bristol-Myers Squibb discovery head Carl Decicco said: “Bristol-Myers Squibb strives to discover and develop transformational therapies that arrest or reverse the progression of fibrosis and restore organ function.

“We believe this collaboration will advance fibrosis research with a goal of expediting the development of new therapies for patients with these debilitating conditions.”

“We are excited to work with the Harvard Fibrosis Network, as we believe this collaboration will advance fibrosis research with a goal of expediting the development of new therapies for patients with these debilitating conditions.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Affecting various organs or tissues, fibrotic diseases cause injury and chronic inflammation, resulting in collagen deposits and scar formation, which impacts organ function and can lead to organ failure.

BMS believes that new treatments for these diseases are necessary as current options are limited.

Harvard Fibrosis Network lead researcher Joseph Bonventre said: “To accelerate our understanding in this area, we draw on a large accomplished group of investigators at the Harvard Stem Cell Institute who focus on many different organs and biological processes.

“Our collaboration with Bristol-Myers Squibb will advance our efforts to discover and develop fibrosis therapies, because it allows us to combine the best of academic, clinical, and pharmaceutical research practice.”